|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xie D, Marks R, Zhang M, Jiang G, Jatoi A,
Garces YI, Mansfield A, Molina J and Yang P: Nomograms predict
overall survival for patients with small-cell lung cancer
incorporating pretreatment peripheral blood markers. J Thorac
Oncol. 10:1213–1220. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Waqar SN and Morgensztern D: Treatment
advances in small cell lung cancer (SCLC). Pharmacol Ther.
180:16–23. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Karachaliou N, Pilotto S, Lazzari C, Bria
E, de Marinis F and Rosell R: Cellular and molecular biology of
small cell lung cancer: An overview. Transl Lung Cancer Res.
5:2–15. 2016.PubMed/NCBI
|
|
5
|
Sundaresan V, Lin VT, Liang F, Kaye FJ,
Kawabata-Iwakawa R, Shiraishi K, Kohno T, Yokota J and Zhou L:
Significantly mutated genes and regulatory pathways in SCLC-a
meta-analysis. Cancer Genet. 216-217:20–28. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Udagawa H, Umemura S, Murakami I, Mimaki
S, Makinoshima H, Ishii G, Miyoshi T, Kirita K, Matsumoto S, Yoh K,
et al: Genetic profiling-based prognostic prediction of patients
with advanced small-cell lung cancer in large scale analysis. Lung
Cancer. 126:182–188. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sakre N, Wildey G, Behtaj M, Kresak A,
Yang M, Fu P and Dowlati A: RICTOR amplification identifies a
subgroup in small cell lung cancer and predicts response to drugs
targeting mTOR. Oncotarget. 8:5992–6002. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sharma SK, Chintala NK, Vadrevu SK, Patel
J, Karbowniczek M and Markiewski MM: Pulmonary alveolar macrophages
contribute to the premetastatic niche by suppressing antitumor T
cell responses in the lungs. J Immunol. 194:5529–5538. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Poirier JT, Gardner EE, Connis N, Moreira
AL, De Stanchina E, Hann CL and Rudin CM: DNA methylation in small
cell lung cancer defines distinct disease subtypes and correlates
with high expression of EZH2. Oncogene. 34:5869–5878. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Valencia-Sanchez MA, Liu J, Hannon GJ and
Parker R: Control of translation and mRNA degradation by miRNAs and
siRNAs. Genes Development. 20:515–524. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Catto JW, Antonio A, Bjartell AS, De Vere
White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L,
Schlomm T and Visakorpi T: MicroRNA in prostate, bladder, and
kidney cancer: A systematic review. Eur Urol. 59:671–681. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iqbal MA, Arora S, Prakasam G, Calin GA
and Syed MA: MicroRNA in lung cancer: Role, mechanisms, pathways
and therapeutic relevance. Mol Aspects Med. 2018.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao Z, Liu J, Wang C, Wang Y, Jiang Y and
Guo M: MicroRNA-25 regulates small cell lung cancer cell
development and cell cycle through cyclin E2. Int J Clin Exp
Pathol. 7:7726–7734. 2014.PubMed/NCBI
|
|
14
|
Grimolizzi F, Monaco F, Leoni F, Bracci M,
Staffolani S, Bersaglieri C, Gaetani S, Valentino M, Amati M,
Rubini C, et al: Exosomal miR-126 as a circulating biomarker in
non-small-cell lung cancer regulating cancer progression. Sci Rep.
7:152772017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Grosso S, Doyen J, Parks SK, Bertero T,
Paye A, Cardinaud B, Gounon P, Lacas-Gervais S, Noel A, Pouyssegur
J, et al: MiR-210 promotes a hypoxic phenotype and increases
radioresistance in human lung cancer cell lines. Cell Death Dis.
4:e5442013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rohrbeck A, Neukirchen J, Rosskopf M,
Pardillos GG, Geddert H, Schwalen A, Gabbert HE, von Haeseler A,
Pitschke G, Schott M, et al: Gene expression profiling for
molecular distinction and characterization of laser captured
primary lung cancers. J Transl Med. 6:692008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gautier L, Cope L, Bolstad BM and Irizarry
RA: Affy-analysis of Affymetrix GeneChip data at the probe level.
Bioinformatics. 20:307–315. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Diboun I, Wernisch L, Orengo CA and
Koltzenburg M: Microarray analysis after RNA amplification can
detect pronounced differences in gene expression using limma. BMC
Genomics. 7:2522006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dennis G Jr, Sherman BT, Hosack DA, Yang
J, Gao W, Lane HC and Lempicki RA: DAVID: Database for annotation,
visualization, and integrated discovery. Genome Biol. 4:P32003.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Assenov Y, Ramirez F, Schelhorn SE,
Lengauer T and Albrecht M: Computing topological parameters of
biological networks. Bioinformatics. 24:282–284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk-Database: Prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma N and Gao X: β-Actin is predicted as
one of the potential targets of miR-145: Choose internal control
gene in verification of microRNA target. Carcinogenesis.
34:2362013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang X: miRDB: A microRNA target
prediction and functional annotation database with a wiki
interface. RNA. 14:1012–1017. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Koinis F, Kotsakis A and Georgoulias V:
Small cell lung cancer (SCLC): No treatment advances in recent
years. Transl Lung Cancer Res. 5:39–50. 2016.PubMed/NCBI
|
|
25
|
Travis WD: Update on small cell carcinoma
and its differentiation from squamous cell carcinoma and other
non-small cell carcinomas. Mod Pathol. 25 (Suppl 1):S18–S30. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Issaeva N: p53 signaling in cancers.
Cancers (Basel). 11:E3322019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dominguez-Brauer C, Thu KL, Mason JM,
Blaser H, Bray MR and Mak TW: Targeting mitosis in cancer: Emerging
strategies. Mol Cell. 60:524–536. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Penna LS, Henriques JAP and Bonatto D:
Anti-mitotic agents: Are they emerging molecules for cancer
treatment? Pharmacol Ther. 173:67–82. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Warkentin MT, Morris D, Bebb G and Brenner
DR: The role of DNA repair capacity on lung cancer risk in
never-smokers: A systematic review of epidemiologic studies. Cancer
Treat Res Commun. 13:13–24. 2017. View Article : Google Scholar
|
|
30
|
Jeggo PA, Pearl LH and Carr AM: DNA
repair, genome stability and cancer: A historical perspective. Nat
Rev Cancer. 16:35–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reis ES, Mastellos DC, Ricklin D,
Mantovani A and Lambris JD: Complement in cancer: Untangling an
intricate relationship. Nat Rev Immunol. 18:5–18. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Afshar-Kharghan V: The role of the
complement system in cancer. J Clin Invest. 127:780–789. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ajona D, Ortiz-Espinosa S, Moreno H,
Lozano T, Pajares MJ, Agorreta J, Bertolo C, Lasarte JJ, Vicent S,
Hoehlig K, et al: A combined PD-1/C5a blockade synergistically
protects against lung cancer growth and metastasis. Cancer Discov.
7:694–703. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wen P, Chidanguro T, Shi Z, Gu H, Wang N,
Wang T, Li Y and Gao J: Identification of candidate biomarkers and
pathways associated with SCLC by bioinformatics analysis. Mol Med
Rep. 18:1538–1550. 2018.PubMed/NCBI
|
|
35
|
Neubauer E, Wirtz RM, Kaemmerer D,
Athelogou M, Schmidt L, Sanger J and Lupp A: Comparative evaluation
of three proliferation markers, Ki-67, TOP2A, and RacGAP1, in
bronchopulmonary neuroendocrine neoplasms: Issues and prospects.
Oncotarget. 7:41959–41973. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang WC, Chin TM, Yang H, Nga ME, Lunny
DP, Lim EK, Sun LL, Pang YH, Leow YN, Malusay SR, et al:
Tumour-initiating cell-specific miR-1246 and miR-1290 expression
converge to promote non-small cell lung cancer progression. Nat
Commun. 7:117022016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kottakis F, Polytarchou C, Foltopoulou P,
Sanidas I, Kampranis SC and Tsichlis PN: FGF-2 regulates cell
proliferation, migration, and angiogenesis through an
NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell. 43:285–298. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang JG, Guo JF, Liu DL, Liu Q and Wang
JJ: MicroRNA-101 exerts tumor-suppressive functions in non-small
cell lung cancer through directly targeting enhancer of zeste
homolog 2. J Thorac Oncol. 6:671–678. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Hu J, Wu C, Zhao X and Liu C: The
prognostic value of decreased miR-101 in various cancers: A
meta-analysis of 12 studies. Onco Targets Ther. 10:3709–3718. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Castillo A, Morse HC III, Godfrey VL,
Naeem R and Justice MJ: Overexpression of Eg5 causes genomic
instability and tumor formation in mice. Cancer Res.
67:10138–10147. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Karunagaran S, Subhashchandrabose S, Lee
KW and Meganathan C: Investigation on the isoform selectivity of
novel kinesin-like protein 1 (KIF11) inhibitor using chemical
feature based pharmacophore, molecular docking, and quantum
mechanical studies. Comput Biol Chem. 61:47–61. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Demes M, Aszyk C, Bartsch H, Schirren J
and Fisseler-Eckhoff A: Differential miRNA-expression as an
adjunctive diagnostic tool in neuroendocrine tumors of the lung.
Cancers (Basel). 8:E382016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gao W, Xu J, Liu L, Shen H, Zeng H and Shu
Y: A systematic-analysis of predicted miR-21 targets identifies a
signature for lung cancer. Biomed Pharmacother. 66:21–28. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fabbri M, Paone A, Calore F, Galli R,
Gaudio E, Santhanam R, Lovat F, Fadda P, Mao C, Nuovo GJ, et al:
MicroRNAs bind to Toll-like receptors to induce prometastatic
inflammatory response. Proc Natl Acad Sci USA. 109:E2110–E2116.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Florczuk M, Szpechcinski A and
Chorostowska-Wynimko J: miRNAs as biomarkers and therapeutic
targets in non-small cell lung cancer: Current perspectives.
Targeted Oncol. 12:179–200. 2017. View Article : Google Scholar
|
|
46
|
Fujii K, Miyata Y, Takahashi I, Koizumi H,
Saji H, Hoshikawa M, Takagi M, Nishimura T and Nakamura H:
Differential proteomic analysis between small cell lung carcinoma
(SCLC) and pulmonary carcinoid tumors reveals molecular signatures
for malignancy in lung cancer. Proteomics Clin Appl.
12:e18000152018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Levallet G, Dubois F, Fouret P, Antoine M,
Brosseau S, Bergot E, Beau-Faller M, Gounant V, Brambilla E,
Debieuvre D, et al: MSH2/BRCA1 expression as a DNA-repair signature
predicting survival in early-stage lung cancer patients from the
IFCT-0002 Phase 3 trial. Oncotarget. 8:4313–4329. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bauerschmidt C, Arrichiello C,
Burdak-Rothkamm S, Woodcock M, Hill MA, Stevens DL and Rothkamm K:
Cohesin promotes the repair of ionizing radiation-induced DNA
double-strand breaks in replicated chromatin. Nucleic Acids Res.
38:477–487. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Urban E, Nagarkar-Jaiswal S, Lehner CF and
Heidmann SK: The cohesin subunit Rad21 is required for synaptonemal
complex maintenance, but not sister chromatid cohesion, during
Drosophila female meiosis. PLoS Genet. 10:e10045402014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu H, Yan Y, Deb S, Rangasamy D, Germann
M, Malaterre J, Eder NC, Ward RL, Hawkins NJ, Tothill RW, et al:
Cohesin Rad21 mediates loss of heterozygosity and is upregulated
via wnt promoting transcriptional dysregulation in gastrointestinal
tumors. Cell Rep. 9:1781–1797. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yan M, Xu H, Waddell N, Shield-Artin K,
Haviv I, kConFab authors, McKay MJ and Fox SB: Enhanced RAD21
cohesin expression confers poor prognosis in BRCA2 and BRCAX, but
not BRCA1 familial breast cancers. Breast Cancer Res. 14:R692012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
Large-scale meta-analysis of cancer microarray data identifies
common transcriptional profiles of neoplastic transformation and
progression. Proc Natl Acad Sci USA. 101:9309–9314. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ranade AR, Cherba D, Sridhar S, Richardson
P, Webb C, Paripati A, Bowles B and Weiss GJ: MicroRNA 92a-2*: A
biomarker predictive for chemoresistance and prognostic for
survival in patients with small cell lung cancer. J Thorac Oncol.
5:1273–1278. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bi J, Zeng X, Zhao L, Wei Q, Yu L, Wang X,
Yu Z, Cao Y, Shan F and Wei M: miR-181a induces macrophage
polarized to M2 phenotype and promotes M2 macrophage-mediated tumor
cell metastasis by targeting KLF6 and C/EBPalpha. Mol Ther Nucleic
Acids. 5:e3682016. View Article : Google Scholar : PubMed/NCBI
|
